Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 1, 2013, Pages 87-94

  Liu, Albert Y ^a,b   Vittinghoff, Eric ^b   Chillag, Kata ^c   Mayer, Kenneth ^d,g   Thompson, Melanie ^e   Grohskopf, Lisa ^c   Colfax, Grant ^a,b   Pathak, Sonal ^f   Gvetadze, Roman ^c   O'Hara, Brandon ^f   Collins, Brandi ^f   Ackers, Marta ^c   Paxton, Lynn ^c   Buchbinder, Susan P ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d FENWAY INSTITUTE   (United States)

^e AIDS Research Consortium of Atlanta   (United States)

^f NORTHROP GRUMMAN CORPORATION   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Behavioral disinhibition; MSM; PrEP; Risk compensation; Sexual risk behavior

Indexed keywords

AMPHETAMINE; AMYL NITRATE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MONITORING; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF REPORT; SEXUAL BEHAVIOR; STRUCTURED INTERVIEW; THERAPY DELAY; UNITED STATES; UNPROTECTED SEX;

ADENINE; ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; ANTI-HIV AGENTS; BOSTON; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GEORGIA; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HIV SERONEGATIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RISK ASSESSMENT; RISK-TAKING; SAN FRANCISCO; SEXUAL PARTNERS; TREATMENT OUTCOME; UNSAFE SEX;

EID: 84883447723     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828f097a     Document Type: Article

References (31)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599
2. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis. 2012;25:51-57
3. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422
4. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA. Abstract 26LB. 3-6 March 2013
5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410
6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434
7. Smith D, Grant R, Weidle P, et al. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68
8. Smith D, Thigpen M, Nesheim S, et al. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61:586-589
9. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380:325
10. Cassell MM, Halperin DT, Shelton JD, et al. Risk compensation: The Achilles' heel of innovations in HIV preventioñ BMJ. 2006;332: 605-607
11. Eaton LA, Kalichman S. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4:165-172
12. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: Empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7:201-209
13. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: A simulation study. PLoS One. 2008;3:e2077
14. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829-1839
15. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806-815
16. Hallett TB, Singh K, Smith JA, et al. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One. 2008;3:e2212
17. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 Trial. PLoS Med. 2005;2:e298
18. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet. 2007;369:643-656
19. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:90-101
20. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35:1002-1008
21. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168- 1174
22. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20:731-739
23. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010;376:458-474
24. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2005;39:82-89
25. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502
26. Golden MR, Dombrowski JC, Kerani RP, et al. Failure of serosorting to protect African American men who have sex with men from HIV infection. Sex Transm Dis. 2012;39:659-664
27. Millett GA, Flores SA, Peterson JL, et al. Explaining disparities in HIV infection among black and white men who have sex with men: A metaanalysis of HIV risk behaviors. AIDS. 2007;21:2083-2091
28. Hurt CB, Beagle S, Leone PA, et al. Investigating a sexual network of black men who have sex with men: Implications for transmission and prevention of HIV infection in the United States. J Acquir Immune Defic Syndr. 2012;61:515-521
29. Nelson KM, Thiede H, Hawes SE, et al. Why the wait? Delayed HIV diagnosis among men who have sex with men. J Urban Health. 2010;87: 642-655
30. Smith A, Miles I, Le B, et al. Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2010;59:1201-1207
31. Vallabhaneni S, Li X, Vittinghoff E, et al. Seroadaptive practices: Association with HIV acquisition among HIV-negative men who have sex with men. PLoS One. 2012;7:e45718